Katharina Timper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katharina Timper has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Mirjam Christ-Crain
Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , 4031 Basel
3 shared publications Christoph Stettler
2 shared publications- Mira Katan
Universitätsspital Basel
2 shared publications Nica Frech
2 shared publicationsAndreas Häring
Department of Surgery (R.P., A.H.), St. Claraspital Basel, CH-4061 Basel, Switzerland
1 shared publication- Anne Blanchard
Université de Paris, Assistance Publique des Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Centre d’Investigations Cliniques, Inserm CIC1318 et UMR 1138, 75015 Paris, France
1 shared publication
Latest Publications
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Plasma apelin concentrations in patients with polyuria-polydipsia syndrome
Background: Apelin and arginine-vasopressin (AVP) are antagonists in the regulation of body fluid and osmotic homeostasis. So far there exist no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS). Methods: Plasma apelin and copeptin concentrations were measured in 15 patients with complete central diabetes insipidus (cDI), in seven patients with complete nephrogenic diabetes insipidus (nDI) and 19 patients with primary polydipsia (PP) and were compared to those in 113 healthy volunteers. Results: Median plasma apelin levels were highest in patients with nDI (413 pmol/l (IQR 332; 504), P=0.01) and lower in patients with PP (190 pmol/l (172; 215), P0.9) was similar to healthy volunteers (57 pmol/pmol (37; 102)). In contrast, apelin to copeptin ratio was higher in patients with cDI (89 pmol/pmol (73; 135), P=0.02) and lower in patients with nDI (7 pmol/pmol (6; 10), P<0.001) compared to healthy volunteers. Conclusion: In PP, normal plasma apelin to copeptin ratio attests a normal water homeostasis. In contrast, in patients with cDI or nDI the increased or decreased apelin to copeptin ratio, respectively, reflects a disturbed osmotic and body fluid homeostasis.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Plasma apelin concentrations in patients with polyuria-polydipsia syndrome
Background: Apelin and arginine-vasopressin (AVP) are antagonists in the regulation of body fluid and osmotic homeostasis. So far there exist no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS). Methods: Plasma apelin and copeptin concentrations were measured in 15 patients with complete central diabetes insipidus (cDI), in seven patients with complete nephrogenic diabetes insipidus (nDI) and 19 patients with primary polydipsia (PP) and were compared to those in 113 healthy volunteers. Results: Median plasma apelin levels were highest in patients with nDI (413 pmol/l (IQR 332; 504), P=0.01) and lower in patients with PP (190 pmol/l (172; 215), P0.9) was similar to healthy volunteers (57 pmol/pmol (37; 102)). In contrast, apelin to copeptin ratio was higher in patients with cDI (89 pmol/pmol (73; 135), P=0.02) and lower in patients with nDI (7 pmol/pmol (6; 10), P<0.001) compared to healthy volunteers. Conclusion: In PP, normal plasma apelin to copeptin ratio attests a normal water homeostasis. In contrast, in patients with cDI or nDI the increased or decreased apelin to copeptin ratio, respectively, reflects a disturbed osmotic and body fluid homeostasis.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Copeptin in the diagnosis and differential diagnosis of diabetes dnsipidus - the 'CoSIP-study'
Introduction: The correct differential diagnosis of the disorders related to polyuria–polydipsia syndrome (PPS) is mandatory since inadequate treatment may lead to serious complications. The diagnostic gold standard is the water deprivation test (WDT) with direct or indirect measurement of plasma vasopressin (AVP). But test interpretation is problematic, and direct measurement of AVP is hampered by methodological difficulties. The aim of this study was to evaluate the diagnostic accuracy of copeptin in the differential diagnosis of DI. Methods: In a prospective multicenter study, patients with a history of PPS and indication for a WDT were consecutively included. The WDT started at 0800 h with a baseline blood and urine sampling and was terminated once S-Na+ levels increased >147 mmol/l. If this cutoff was not reached by fluid deprivation alone, a 3% saline infusion was administered. Serum samples were obtained hourly for measurement of copeptin and AVP. Results: We present results of the first 52 patients with full data available: 13 with complete, 12 with partial central DI, 17 with PP, and 10 with nephrogenic DI. Twenty-nine were women, 23 were men. Mean (S.D.) age was 45 (16) years. Baseline copeptin levels ranged from 21–117 pmol/L in patients with nephrogenic DI, from 0.7–5.1 pmol/Llin patients with central DI (complete: 0.7–4.1 pmol/l; partial: 0.8–5.1 pmol/l) and from 0.9–13.5 pmol/l in patients with primary polydipsia. Without prior thirsting, a single baseline copeptin level of >20 pmol/l perfectly differentiated nephrogenic DI from all other etiologies with a sensitivity and specificity of 100%, rendering a WDT unnecessary. Furthermore, a delta copeptin increase under osmotic stimulation of <2 pmol/l differentiated patients with central DI from patients with primary polydipsia with a specificity of 95.8%, a sensitivity of 94.1% and a positive likelihood ratio of 22.6. Conclusion: Copeptin is a promising new tool in the complex diagnosis of polyuria–polydipsia syndrome
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Copeptin in the diagnosis and differential diagnosis of diabetes dnsipidus - the 'CoSIP-study'
Introduction: The correct differential diagnosis of the disorders related to polyuria–polydipsia syndrome (PPS) is mandatory since inadequate treatment may lead to serious complications. The diagnostic gold standard is the water deprivation test (WDT) with direct or indirect measurement of plasma vasopressin (AVP). But test interpretation is problematic, and direct measurement of AVP is hampered by methodological difficulties. The aim of this study was to evaluate the diagnostic accuracy of copeptin in the differential diagnosis of DI. Methods: In a prospective multicenter study, patients with a history of PPS and indication for a WDT were consecutively included. The WDT started at 0800 h with a baseline blood and urine sampling and was terminated once S-Na+ levels increased >147 mmol/l. If this cutoff was not reached by fluid deprivation alone, a 3% saline infusion was administered. Serum samples were obtained hourly for measurement of copeptin and AVP. Results: We present results of the first 52 patients with full data available: 13 with complete, 12 with partial central DI, 17 with PP, and 10 with nephrogenic DI. Twenty-nine were women, 23 were men. Mean (S.D.) age was 45 (16) years. Baseline copeptin levels ranged from 21–117 pmol/L in patients with nephrogenic DI, from 0.7–5.1 pmol/Llin patients with central DI (complete: 0.7–4.1 pmol/l; partial: 0.8–5.1 pmol/l) and from 0.9–13.5 pmol/l in patients with primary polydipsia. Without prior thirsting, a single baseline copeptin level of >20 pmol/l perfectly differentiated nephrogenic DI from all other etiologies with a sensitivity and specificity of 100%, rendering a WDT unnecessary. Furthermore, a delta copeptin increase under osmotic stimulation of <2 pmol/l differentiated patients with central DI from patients with primary polydipsia with a specificity of 95.8%, a sensitivity of 94.1% and a positive likelihood ratio of 22.6. Conclusion: Copeptin is a promising new tool in the complex diagnosis of polyuria–polydipsia syndrome
- 1 February 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (2) , E297-E303
Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Calcitonin Gene-Related Peptide (CGRP)-I and Procalcitonin (Pro-CT) Production in Human Adipocytes
Context: Increased plasma levels of glucose-dependent insulinotropic polypeptide (GIP), calcitonin CT gene-related peptide (CGRP)-I, and procalcitonin (Pro-CT) are associated with obesity. Adipocytes express functional GIP receptors and the CT peptides Pro-CT and CGRP-I. However, a link between GIP and CT peptides has not been studied yet. Objective: The objective of the study was the assessment of the GIP effect on the expression and secretion of CGRP-I and Pro-CT in human adipocytes, CGRP-I and CT gene expression in adipose tissue (AT) from obese vs. lean subjects, and plasma levels of CGRP-I and Pro-CT after a high-fat meal in obese patients. Design and Participants: Human preadipocyte-derived adipocytes, differentiated in vitro, were treated with GIP. mRNA expression and protein secretion of CGRP-I and Pro-CT were measured. Human CGRP-I and CT mRNA expression in AT and CGRP-I and Pro-CT plasma concentrations were assessed. Results: Treatment with 1 nm GIP induced CGRP-I mRNA expression 6.9 ± 1.0-fold (P < 0.001 vs. control) after 2 h and CT gene expression 14.0 ± 1.7-fold (P < 0.001 vs. control) after 6 h. GIP stimulated CGRP-I secretion 1.7 ± 0.2-fold (P < 0.05 vs. control) after 1 h. In AT samples of obese subjects, CGRP-I mRNA expression was higher in sc AT (P < 0.05 vs. lean subjects), whereas CT expression was higher in visceral AT (P < 0.05 vs. lean subjects). CGRP-I plasma levels increased after a high-fat meal in obese patients. Conclusion: GIP induces CGRP-I and CT expression in human adipocytes. Therefore, elevated Pro-CT and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and might be triggered by a high-fat diet. How these findings relate to the metabolic complications of obesity warrants further investigations.
- 1 February 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (2) , E297-E303
Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Calcitonin Gene-Related Peptide (CGRP)-I and Procalcitonin (Pro-CT) Production in Human Adipocytes
Context: Increased plasma levels of glucose-dependent insulinotropic polypeptide (GIP), calcitonin CT gene-related peptide (CGRP)-I, and procalcitonin (Pro-CT) are associated with obesity. Adipocytes express functional GIP receptors and the CT peptides Pro-CT and CGRP-I. However, a link between GIP and CT peptides has not been studied yet. Objective: The objective of the study was the assessment of the GIP effect on the expression and secretion of CGRP-I and Pro-CT in human adipocytes, CGRP-I and CT gene expression in adipose tissue (AT) from obese vs. lean subjects, and plasma levels of CGRP-I and Pro-CT after a high-fat meal in obese patients. Design and Participants: Human preadipocyte-derived adipocytes, differentiated in vitro, were treated with GIP. mRNA expression and protein secretion of CGRP-I and Pro-CT were measured. Human CGRP-I and CT mRNA expression in AT and CGRP-I and Pro-CT plasma concentrations were assessed. Results: Treatment with 1 nm GIP induced CGRP-I mRNA expression 6.9 ± 1.0-fold (P < 0.001 vs. control) after 2 h and CT gene expression 14.0 ± 1.7-fold (P < 0.001 vs. control) after 6 h. GIP stimulated CGRP-I secretion 1.7 ± 0.2-fold (P < 0.05 vs. control) after 1 h. In AT samples of obese subjects, CGRP-I mRNA expression was higher in sc AT (P < 0.05 vs. lean subjects), whereas CT expression was higher in visceral AT (P < 0.05 vs. lean subjects). CGRP-I plasma levels increased after a high-fat meal in obese patients. Conclusion: GIP induces CGRP-I and CT expression in human adipocytes. Therefore, elevated Pro-CT and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and might be triggered by a high-fat diet. How these findings relate to the metabolic complications of obesity warrants further investigations.